2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

World Journal of Hepatology ◽

10.4254/wjh.v6.i10.759 ◽

2014 ◽

Vol 6 (10) ◽

pp. 759 ◽

Cited By ~ 3

Author(s):

Nicolae-Catalin Mechie

Keyword(s):

Protease Inhibitor ◽

Triple Therapy ◽

Meta Analysis ◽

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Chronic Hcv

OC-31 Low rates of SVR to peg-interferon plus ribavirin in HCV genotype 1 IL28B rs12979860 CC cirrhotic patients without rapid virological response

Digestive and Liver Disease ◽

10.1016/s1590-8658(12)60032-2 ◽

2012 ◽

Vol 44 ◽

pp. S11

Author(s):

E. Degasperi ◽

A. Aghemo ◽

E. Galmozzi ◽

L. Valenti ◽

S. De Nicola ◽

...

Keyword(s):

Virological Response ◽

Rapid Virological Response ◽

Genotype 1 ◽

Hcv Genotype ◽

Cirrhotic Patients ◽

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)70050-2 ◽

2015 ◽

Vol 15 (4) ◽

pp. 397-404 ◽

Cited By ~ 212

Author(s):

Marc Bourlière ◽

Jean-Pierre Bronowicki ◽

Victor de Ledinghen ◽

Christophe Hézode ◽

Fabien Zoulim ◽

...

Keyword(s):

Protease Inhibitor ◽

Inhibitor Therapy ◽

Protease Inhibitor Therapy ◽

Phase 2 ◽

Genotype 1 ◽

Double Blind ◽

Hcv Genotype ◽

Phase 2 Trial ◽

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Journal of Virus Eradication ◽

10.1016/s2055-6640(20)30043-1 ◽

2019 ◽

Vol 5 (3) ◽

pp. 138-144

Author(s):

Kimberly Struble ◽

Kirk Chan-Tack ◽

Karen Qi ◽

Thamban Valappil ◽

Sarah Connelly ◽

...

Keyword(s):

Clinical Trials ◽

Sustained Virological Response ◽

Virological Response ◽

Response Rates ◽

Genotype 1 ◽

Direct Acting Antivirals ◽

Systematic Analysis ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Direct Acting

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Antiviral Research ◽

10.1016/j.antiviral.2013.05.015 ◽

2013 ◽

Vol 99 (3) ◽

pp. 214-220 ◽

Cited By ~ 25

Author(s):

Eric Lawitz ◽

Mark Sulkowski ◽

Ira Jacobson ◽

Walter K. Kraft ◽

Benedict Maliakkal ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Antiviral Activity ◽

Protease Inhibitor ◽

Genotype 1 ◽

Hcv Genotype ◽

No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.354 ◽

2017 ◽

Vol 7 (2) ◽

pp. 143-150 ◽

Author(s):

Matt S. Anderson ◽

Teddy Kosoglou ◽

Paul Statkevich ◽

Jing Li ◽

Jennifer Rotonda ◽

...

Keyword(s):

Drug Interaction ◽

Healthy Volunteers ◽

Multiple Dose ◽

Dose Administration ◽

Multiple Dose Administration ◽

Drug Drug Interaction ◽

Pharmacokinetic Drug

Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir

Journal of Clinical Virology ◽

10.1016/j.jcv.2015.09.015 ◽

2015 ◽

Vol 72 ◽

pp. 133-140 ◽

Cited By ~ 5

Author(s):

Bart Fevery ◽

Simone Susser ◽

Oliver Lenz ◽

Gavin Cloherty ◽

Dany Perner ◽

...

Keyword(s):

Protease Inhibitor ◽

Hcv Rna ◽

Genotype 1 ◽

Hcv Genotype ◽

[O2-17-04]: PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) EFFECTS OF PF-06648671, A NOVEL GAMMA SECRETASE MODULATOR (GSM), FOLLOWING SINGLE AND MULTIPLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS

Alzheimer s & Dementia ◽

10.1016/j.jalz.2017.07.244 ◽

2017 ◽

Vol 13 (7S_Part_12) ◽

pp. P601-P601 ◽

Author(s):

Jae Eun Ahn ◽

Richann Liu ◽

Patrick Trapa ◽

Kathleen M. Wood ◽

Eva Hajos-Korcsok ◽

...

Keyword(s):

Healthy Volunteers ◽

Multiple Dose ◽

Gamma Secretase ◽

Dose Administration ◽

Multiple Dose Administration

828 TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN OLDER HCV GENOTYPE 1 PATIENTS WITH POSITIVE PROGNOSTIC FACTORS LEADS TO HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE

Journal of Hepatology ◽

10.1016/s0168-8278(08)60830-2 ◽

2008 ◽

Vol 48 ◽

pp. S310 ◽

Author(s):

K.R. Reddy ◽

D. Messinger ◽

M. Popescu ◽

S.J. Hadziyannis

Keyword(s):

Prognostic Factors ◽

Sustained Virological Response ◽

Virological Response ◽

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Peginterferon Alfa

Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration

European Journal of Drug Metabolism and Pharmacokinetics ◽

10.1007/bf03190145 ◽

1992 ◽

Vol 17 (3) ◽

pp. 195-199 ◽

Author(s):

A. Bartlett ◽

A. Costa ◽

L. Martinez ◽

R. Roser ◽

R. Sagarra ◽

...

Keyword(s):

Healthy Volunteers ◽

Multiple Dose ◽

Dose Administration ◽

Multiple Dose Administration